Article
ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Cell communication and signaling : CCS - 13 Oct 2022
Sun Dantong, Qian Haili, Wang Jinsong, Xie Tongji, Teng Fei, Li Junling, Xing Puyuan
Abstract excerpt
INTRODUCTION: EGFR mutations in non-small cell lung cancer (NSCLC) are associated with a poor response to immune checkpoint inhibitors (ICIs), and only 20% of NSCLC patients harboring EGFR mutations benefit from immunotherapy. Novel biomarkers or therapeutics are needed to predict NSCLC prognosis and enhance the efficacy of ICIs in NSCLC patients harboring EGFR mutations, especially lung adenocarcinoma (LUAD)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.